• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对 90 例散发性神经母细胞瘤肿瘤中间变性淋巴瘤激酶 (ALK) 基因的拷贝数状态和突变分析。

Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.

机构信息

Department of Medical Biology and Genetics, Dokuz Eylul University, School of Medicine, Izmir, Turkey.

出版信息

Cancer Lett. 2012 Apr 1;317(1):72-7. doi: 10.1016/j.canlet.2011.11.013. Epub 2011 Nov 13.

DOI:10.1016/j.canlet.2011.11.013
PMID:22085494
Abstract

Somatic and germline mutations of the anaplastic lymphoma kinase (ALK) gene were recently described in neuroblastoma (NB). In this study, we investigated the association of ALK copy number alterations with copy number status 2p24.1 amplicon harboring DEAD box polypeptide 1 (DDX1), MYCN and neuroblastoma-amplified (NAG) genes in 90 primary tumors of sporadic NB cases by multiplex ligation-dependent probe amplification (MLPA). We also performed mutation analysis of ALK gene by directly sequencing the exons 20-28 which cover the region that encodes juxtamembrane and kinase domains. A total of 39 (43.3%) NB cases revealed copy numbers alterations of ALK gene. There was highly significant association of ALK copy number gains with gains of one or more of the genes at 2p24.1 (DDX1, MYCN or NAG) in MYCN unamplified tumors (P<0.000). In addition, 15 of 17 MYCN amplified cases (88.2%) had aberrant ALK status. Solitary gain of ALK with normal copy number status of all other genes was observed only in one case. DNA sequencing of exons 20-28 of ALK revealed two different nucleotide changes in three cases leading to amino acid substitutions of F1245V and R1275Q in tyrosine kinase domain. In conclusion, the frequency of ALK mutations in NB is low and solitary copy number change of it is rarely observed.

摘要

ALK 基因的体细胞和种系突变最近在神经母细胞瘤 (NB) 中被描述。在这项研究中,我们通过多重连接依赖性探针扩增 (MLPA) 检测了 90 例散发性 NB 原发肿瘤中 ALK 拷贝数改变与 2p24.1 扩增子中 DEAD 框多肽 1 (DDX1)、MYCN 和神经母细胞瘤扩增 (NAG) 基因的拷贝数状态之间的关联。我们还通过直接测序外显子 20-28 对 ALK 基因进行了突变分析,该区域编码跨膜区和激酶结构域。共有 39 例 (43.3%) NB 病例显示 ALK 基因拷贝数改变。在 MYCN 未扩增的肿瘤中,ALK 拷贝数增加与 2p24.1 上一个或多个基因 (DDX1、MYCN 或 NAG) 的获得高度相关 (P<0.000)。此外,17 例 MYCN 扩增病例中有 15 例 (88.2%) 存在异常 ALK 状态。仅在 1 例中观察到 ALK 单独获得,而所有其他基因的拷贝数均正常。ALK 外显子 20-28 的 DNA 测序显示,在 3 例中发现了两种不同的核苷酸变化,导致酪氨酸激酶结构域中的 F1245V 和 R1275Q 氨基酸取代。总之,NB 中 ALK 突变的频率较低,很少观察到其单独的拷贝数改变。

相似文献

1
Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.对 90 例散发性神经母细胞瘤肿瘤中间变性淋巴瘤激酶 (ALK) 基因的拷贝数状态和突变分析。
Cancer Lett. 2012 Apr 1;317(1):72-7. doi: 10.1016/j.canlet.2011.11.013. Epub 2011 Nov 13.
2
Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.DDX1和NAG基因扩增/过表达与MYCN扩增型神经母细胞瘤患者预后的关系。
J Cancer Res Clin Oncol. 2007 Mar;133(3):185-92. doi: 10.1007/s00432-006-0156-y. Epub 2006 Oct 7.
3
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.神经母细胞瘤的荟萃分析显示,具有 MYCN 扩增的肿瘤中存在偏斜的 ALK 突变谱。
Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18.
4
Concomitant DDX1 and MYCN gain in neuroblastoma.神经母细胞瘤中DDX1和MYCN的同时获得。
Cancer Lett. 2007 Oct 18;256(1):56-63. doi: 10.1016/j.canlet.2007.05.010. Epub 2007 Jul 3.
5
Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.间变性淋巴瘤激酶(ALK)调节神经母细胞瘤细胞中 MYCN 转录的起始。
Oncogene. 2012 Dec 13;31(50):5193-200. doi: 10.1038/onc.2012.12. Epub 2012 Jan 30.
6
Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.DDX1的共扩增与MYCN扩增的人类神经母细胞瘤患儿的生存概率提高相关。
J Clin Oncol. 2004 Jul 1;22(13):2681-90. doi: 10.1200/JCO.2004.07.192.
7
ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.ALK(R1275Q) 扰乱细胞外基质,增强细胞侵袭能力,并与 MYCN 协同导致神经母细胞瘤的发生。
Oncogene. 2016 Aug 25;35(34):4447-58. doi: 10.1038/onc.2015.519. Epub 2016 Feb 1.
8
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.在ALK突变的神经母细胞瘤中联合使用PI3K/AKT/mTOR通路抑制剂与克唑替尼的分子原理。
Oncotarget. 2014 Sep 30;5(18):8737-49. doi: 10.18632/oncotarget.2372.
9
ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.使用三种抗体检测神经母细胞瘤中ALK基因拷贝数增加及免疫组化表达状态
Pediatr Dev Pathol. 2017 Mar-Apr;20(2):133-141. doi: 10.1177/1093526616686445. Epub 2017 Jan 25.
10
The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.第二代ALK抑制剂阿来替尼可有效诱导人神经母细胞瘤细胞凋亡,并在TH-MYCN转基因神经母细胞瘤小鼠模型中抑制肿瘤生长。
Cancer Lett. 2017 Aug 1;400:61-68. doi: 10.1016/j.canlet.2017.04.022. Epub 2017 Apr 26.

引用本文的文献

1
15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL.从出生到青春期的15岁间的ALK基因;在神经母细胞瘤中的走向
Curr Oncol Rep. 2025 Apr;27(4):431-445. doi: 10.1007/s11912-025-01650-w. Epub 2025 Mar 11.
2
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment.小分子酪氨酸激酶抑制剂(TKIs)治疗脑胶质瘤。
Int J Mol Sci. 2024 Jan 23;25(3):1398. doi: 10.3390/ijms25031398.
3
Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.肺腺癌患者同时存在 DCTN1-ALK 和 ALK-CLIP4 重排对 ALK-TKIs 的反应。
Thorac Cancer. 2022 Apr;13(7):1088-1090. doi: 10.1111/1759-7714.14345. Epub 2022 Feb 24.
4
Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer.定义神经母细胞瘤(一种源于神经嵴的癌症)中 ALK 的病理性活动。
Int J Mol Sci. 2021 Oct 29;22(21):11718. doi: 10.3390/ijms222111718.
5
The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development.MYCN、Trk 和 ALK 基因在神经母细胞瘤和神经发育中的作用。
Surg Today. 2019 Sep;49(9):721-727. doi: 10.1007/s00595-019-01790-0. Epub 2019 Mar 8.
6
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human mutant neuroblastoma cell lines and xenograft models.联合抑制ALK和MDM2可增强人突变神经母细胞瘤细胞系和异种移植模型的抗肿瘤活性并克服耐药性。
Elife. 2017 Apr 20;6:e17137. doi: 10.7554/eLife.17137.
7
ALK: a tyrosine kinase target for cancer therapy.间变性淋巴瘤激酶:癌症治疗的酪氨酸激酶靶点。
Cold Spring Harb Mol Case Stud. 2017 Jan;3(1):a001115. doi: 10.1101/mcs.a001115.
8
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.ALK突变在神经母细胞瘤中赋予不同的致癌激活作用以及对ALK抑制疗法的敏感性。
Cancer Cell. 2014 Nov 10;26(5):682-94. doi: 10.1016/j.ccell.2014.09.019.
9
ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.ALK 基因拷贝数增加及其在肝细胞癌中的临床意义。
World J Gastroenterol. 2014 Jan 7;20(1):183-92. doi: 10.3748/wjg.v20.i1.183.
10
Increased ALK1 copy number and renal cell carcinoma-a case report.ALK1 拷贝数增加与肾细胞癌—病例报告。
Virchows Arch. 2014 Feb;464(2):241-5. doi: 10.1007/s00428-013-1520-3. Epub 2013 Dec 7.